Drug development sed can use a CTS to characterize the interactions between drugs and diseases, so that will include the evaluation of disease-modifying CCT239065 effects, dose selection and the effects of covariates. In conjunction with a test model, erm glicht the evaluation of CTS these interactions, given the uncertainties and factors of study design, including normal to the impact of different statistical methods for data analysis Eur J Clin Pharmacol S82 67: S75, S86, in a meta Analysis be included. Second, it is difficult to determine the influence of design Separate changes, w During CTS erm Glicht the assessment of a single factor at a time.
Although meta-analyzes provide k Can provide valuable information about the differences in patient populations and response to treatment, it CCT239065 1163719-51-4 is unfortunate that many researchers consider the contr The entire publication sufficient to gather evidence on the r Of the design factors, such as often suggested in the analysis of the meta-analysis. If the simulated data with real patient data to be exchanged, it is unerl Ugly, that the model parameters, not only not biased, but the variability of t is Sch Estimates are accurate. Often the interpretation of the results of statistical models is focused on the predicted values of the treatment effect. This does not zwangsl Frequently that the response distributions reflect what real in the patient population. In fact, it is not ungew Similar, mis-specification of models of variability inflated t be corrected.
It is therefore important to understand to take Doctors that the standard does not take into account the goodness of fit criteria, the properties of the simulation and therefore can not repr His sentative of the best model. Such a comparison between simulated data and background can be with graphical and statistical tools. CTS will investigate according to the availability of accurate model parameters and distributions, these ifscenarios a number of different conditions or design features as size E of Bev Lkerung, levels of stratification, dose range, the plan based survey, and the endpoints that also different. A big advantage of such a virtual experience he or statistics is the F Ability to predict the performance of the study, and thus m Adjusted restrictions in the investigation and design of the protocol to identify before being implemented.
In fact, some simulations of clinical trials for the results of the tests is evaluated. They demonstrated the accuracy and important correspondence between simulation and real results. For example, Nguyen et al. developed a new treatment regimen for busulfan in S uglingen, have children and youth through the use of population pharmacokinetic model. The new scheme has been accepted and as a conditioning regimen prior to h Hematopoietic accepted Etic stem cell transplantation for p Pediatric patients since 2005. Another example of rational drug design dosage is shown in the study of Laer et al. Population pharmacokinetic modeling and simulations were used to age-appropriate dosing regimens for sotalol in children with supraventricular Ren to develop tachycardia. Children.6 for years, the dose was determined h Higher than the neonatal and children.6 years. M & S and personalized medicines An STC is one of the most obvious possibilities M, The concept of personalized medicine and its implications in clinical practice. M & S techniques are used to identify subgroups of patients and the dosage regimen for specific subsets of Bev Lkerung set. PBPK-PD models, pop and PK PKPD models, as well as